Thrombotic thrombocytopenic purpura screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 15: Line 15:
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
==Screening==
==Screening==
There is insufficient evidence to recommend routine screening for [disease/malignancy].
There is no insufficient evidence to recommend routine screening for TTP.


OR
First test to be performe for TTP is screening for ADAMTS13 activity.
 
*ADAMTS13 activity < 10%, TTP diagnosis is confirmed.
According to the [guideline name], screening for [disease name] is not recommended.
 
OR
 
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
*[Condition 1]
*[Condition 2]
*[Condition 3]


==References==
==References==

Revision as of 20:02, 13 September 2018

Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura screening

CDC on Thrombotic thrombocytopenic purpura screening

Thrombotic thrombocytopenic purpura screening in the news

Blogs on Thrombotic thrombocytopenic purpura screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].

Screening

There is no insufficient evidence to recommend routine screening for TTP.

First test to be performe for TTP is screening for ADAMTS13 activity.

  • ADAMTS13 activity < 10%, TTP diagnosis is confirmed.

References

Template:WH Template:WS